Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B

Y Bai, X Wu, KM Brennan, DS Wang, M D'Antonio, J Moran, J Svaren, ME Shy

Research output: Contribution to journalArticle

Abstract

Objective: To determine the prevalence of MPZ mutations that cause Charcot Marie Tooth neuropathy type 1B (CMT1B) and activate the unfolded protein Response (UPR). Background: CMT1B is caused by > 200 heterozygous mutations in MPZ, the major protein in peripheral nerve myelin. Mutations Ser63del MPZ and Arg98Cys MPZ cause the mutant protein to be retained in the ER and activate the generally adaptive UPR. Treatments that modulate UPR activation have improved cellular and rodent models of CMT1B raising the possibility that other MPZ mutations that activate the UPR would also respond favorably to similar treatment. The prevalence of MPZ mutations that activate the UPR is unknown. Methods: We developed a dual luciferase reporter assay of Xbp1 splicing using stably transfected RT4 Schwann cells to assay the ability of cDNA constructs bearing 46 distinct MPZ mutations to activate the UPR. Constructs also carried an HA tag to permit detection of ER retention of mutant proteins. UPR activation and ER retention were correlated with clinical phenotypes. Results: Eighteen mutations demonstrated ER retention and UPR activation to a similar degree as Ser63del and Arg98Cys MPZ. Thirty-five of the mutations activated the UPR > 1.5 fold compared to that of wild-type MPZ. Correlation was high between firefly and Nano-luciferase reporters and between both reporters and ER localization. UPR activity did not correlate with clinical onset or severity. Conclusion: Many CMT1B causing mutations activate the UPR and may be susceptible to therapeutic efforts to facilitate UPR function. © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Original languageEnglish
Pages (from-to)445-455
Number of pages11
JournalAnnals of Clinical and Translational Neurology
Volume5
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Myelin P0 Protein
Charcot-Marie-Tooth Disease
Unfolded Protein Response
Mutation
Mutant Proteins
Firefly Luciferases
Schwann Cells
Neurology
Myelin Sheath
Luciferases
Peripheral Nerves

Cite this

Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. / Bai, Y; Wu, X; Brennan, KM; Wang, DS; D'Antonio, M; Moran, J; Svaren, J; Shy, ME.

In: Annals of Clinical and Translational Neurology, Vol. 5, No. 4, 2018, p. 445-455.

Research output: Contribution to journalArticle

Bai, Y ; Wu, X ; Brennan, KM ; Wang, DS ; D'Antonio, M ; Moran, J ; Svaren, J ; Shy, ME. / Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. In: Annals of Clinical and Translational Neurology. 2018 ; Vol. 5, No. 4. pp. 445-455.
@article{12d3e5865ab844acbcd85a6917dd9d59,
title = "Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B",
abstract = "Objective: To determine the prevalence of MPZ mutations that cause Charcot Marie Tooth neuropathy type 1B (CMT1B) and activate the unfolded protein Response (UPR). Background: CMT1B is caused by > 200 heterozygous mutations in MPZ, the major protein in peripheral nerve myelin. Mutations Ser63del MPZ and Arg98Cys MPZ cause the mutant protein to be retained in the ER and activate the generally adaptive UPR. Treatments that modulate UPR activation have improved cellular and rodent models of CMT1B raising the possibility that other MPZ mutations that activate the UPR would also respond favorably to similar treatment. The prevalence of MPZ mutations that activate the UPR is unknown. Methods: We developed a dual luciferase reporter assay of Xbp1 splicing using stably transfected RT4 Schwann cells to assay the ability of cDNA constructs bearing 46 distinct MPZ mutations to activate the UPR. Constructs also carried an HA tag to permit detection of ER retention of mutant proteins. UPR activation and ER retention were correlated with clinical phenotypes. Results: Eighteen mutations demonstrated ER retention and UPR activation to a similar degree as Ser63del and Arg98Cys MPZ. Thirty-five of the mutations activated the UPR > 1.5 fold compared to that of wild-type MPZ. Correlation was high between firefly and Nano-luciferase reporters and between both reporters and ER localization. UPR activity did not correlate with clinical onset or severity. Conclusion: Many CMT1B causing mutations activate the UPR and may be susceptible to therapeutic efforts to facilitate UPR function. {\circledC} 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",
author = "Y Bai and X Wu and KM Brennan and DS Wang and M D'Antonio and J Moran and J Svaren and ME Shy",
year = "2018",
doi = "10.1002/acn3.543",
language = "English",
volume = "5",
pages = "445--455",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B

AU - Bai, Y

AU - Wu, X

AU - Brennan, KM

AU - Wang, DS

AU - D'Antonio, M

AU - Moran, J

AU - Svaren, J

AU - Shy, ME

PY - 2018

Y1 - 2018

N2 - Objective: To determine the prevalence of MPZ mutations that cause Charcot Marie Tooth neuropathy type 1B (CMT1B) and activate the unfolded protein Response (UPR). Background: CMT1B is caused by > 200 heterozygous mutations in MPZ, the major protein in peripheral nerve myelin. Mutations Ser63del MPZ and Arg98Cys MPZ cause the mutant protein to be retained in the ER and activate the generally adaptive UPR. Treatments that modulate UPR activation have improved cellular and rodent models of CMT1B raising the possibility that other MPZ mutations that activate the UPR would also respond favorably to similar treatment. The prevalence of MPZ mutations that activate the UPR is unknown. Methods: We developed a dual luciferase reporter assay of Xbp1 splicing using stably transfected RT4 Schwann cells to assay the ability of cDNA constructs bearing 46 distinct MPZ mutations to activate the UPR. Constructs also carried an HA tag to permit detection of ER retention of mutant proteins. UPR activation and ER retention were correlated with clinical phenotypes. Results: Eighteen mutations demonstrated ER retention and UPR activation to a similar degree as Ser63del and Arg98Cys MPZ. Thirty-five of the mutations activated the UPR > 1.5 fold compared to that of wild-type MPZ. Correlation was high between firefly and Nano-luciferase reporters and between both reporters and ER localization. UPR activity did not correlate with clinical onset or severity. Conclusion: Many CMT1B causing mutations activate the UPR and may be susceptible to therapeutic efforts to facilitate UPR function. © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

AB - Objective: To determine the prevalence of MPZ mutations that cause Charcot Marie Tooth neuropathy type 1B (CMT1B) and activate the unfolded protein Response (UPR). Background: CMT1B is caused by > 200 heterozygous mutations in MPZ, the major protein in peripheral nerve myelin. Mutations Ser63del MPZ and Arg98Cys MPZ cause the mutant protein to be retained in the ER and activate the generally adaptive UPR. Treatments that modulate UPR activation have improved cellular and rodent models of CMT1B raising the possibility that other MPZ mutations that activate the UPR would also respond favorably to similar treatment. The prevalence of MPZ mutations that activate the UPR is unknown. Methods: We developed a dual luciferase reporter assay of Xbp1 splicing using stably transfected RT4 Schwann cells to assay the ability of cDNA constructs bearing 46 distinct MPZ mutations to activate the UPR. Constructs also carried an HA tag to permit detection of ER retention of mutant proteins. UPR activation and ER retention were correlated with clinical phenotypes. Results: Eighteen mutations demonstrated ER retention and UPR activation to a similar degree as Ser63del and Arg98Cys MPZ. Thirty-five of the mutations activated the UPR > 1.5 fold compared to that of wild-type MPZ. Correlation was high between firefly and Nano-luciferase reporters and between both reporters and ER localization. UPR activity did not correlate with clinical onset or severity. Conclusion: Many CMT1B causing mutations activate the UPR and may be susceptible to therapeutic efforts to facilitate UPR function. © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

U2 - 10.1002/acn3.543

DO - 10.1002/acn3.543

M3 - Article

VL - 5

SP - 445

EP - 455

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 4

ER -